Eiger BioPharmaceuticals, Inc. — Cyborg Score 2/10
Challenged
Biotechnology - Rare/Orphan Diseases
Strategic Profile
Prior to bankruptcy, Eiger positioned itself as a commercial-stage biotech with lonafarnib (Zokinvy) as its lead candidate for HDV and progeria-related diseases. The company's pipeline included avexitide for post-bariatric hypoglycemia, though the asset was sold during bankruptcy proceedings (April 2024 to Amylyx Pharmaceuticals). The company operates in a competitive rare disease space against specialized biotechs focused on orphan indications.
Cyborg Score Rationale
Eiger is in Chapter 11 bankruptcy restructuring with minimal market capitalization ($12.59M as of March 2026). The company faces significant financial constraints, negative cash burn, and operational uncertainty typical of companies in bankruptcy. However, it retains intellectual property and regulatory approvals for Zokinvy in Japan (approved with partner AnGes), which may provide post-emergence value.
Top Insights
Filed for Chapter 11 bankruptcy in April 2024, significantly disrupting commercial operations and investor confidence
Divested avexitide asset to Amylyx Pharmaceuticals during bankruptcy proceedings, reducing pipeline depth
Zokinvy (lonafarnib) approved in Japan (2024) for Hutchinson-Gilford Progeria Syndrome in partnership with AnGes, representing potential post-emergence value
Market capitalization collapsed to $12.59M (March 2026) with stock trading below $10, reflecting bankruptcy status and execution risk
Named Competitors
Soliris (pegcetacoplan) — Complement inhibitor for rare diseases